HighTide Therapeutics, Inc.

君圣泰医药

02511.HK

Develops multifunctional, multi-targeted therapies for metabolic and digestive diseases, with a pipeline led by HTD1801, a gut-liver anti-inflammatory metabolic modulator; operates as a clinical-stage biopharmaceutical company in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Chapter 18A biotech